AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

Sanofi has announced that it will be acquiring Vigil Neuroscience and its investigational Alzheimer’s disease (AD) drug for ...

To help address the impact of COPD on patients and communities, global healthcare companies Sanofi and Regeneron are working together to study the ripple effects of COPD and to help create a ...

Japan’s Nippon Steel is set to finalize its acquisition of U.S. Steel for $55 per share, following a green light from ...

Paris: Sanofi has completed the acquisition of DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio, Inc., a ...

Detailed price information for Vigil Neuroscience Inc (VIGL-Q) from The Globe and Mail including charting and trades.

Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its ...

About a year after investing in Vigil Neuroscience Inc., Sanofi is now acquiring the Watertown biotech and its treatment in ...

Short interest in Vigil Neuroscience Inc (NASDAQ:VIGL) decreased during the last reporting period, falling from 422.30K to 360.67K. This put 1.01% of the company's publicly available shares short.

Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide ...

Sanofi to acquire clinical-stage biotechnology company, Vigil Neuroscience for $470 million: Paris Friday, May 23, 2025, 11:00 Hrs [IST] Sanofi, an innovative global healthcare co ...

French pharma Sanofi has acquired the U.S.-based biotech firm Vigil Neuroscience for $470 million, aiming to bolster its ...